# Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy

> **NCT05844982** · PHASE3 · RECRUITING · sponsor: **Jaeb Center for Health Research** · enrollment: 600 (estimated)

## Conditions studied

- Radiation Retinopathy
- Visual Impairment

## Interventions

- **DRUG:** Faricimab
- **DRUG:** fluocinolone acetonide

## Key facts

- **NCT ID:** NCT05844982
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-21
- **Primary completion:** 2029-12-26
- **Final completion:** 2029-12-26
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05844982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05844982, "Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT05844982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*